Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank93
3Y CAGR+9.6%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+9.6%/yr
Quarterly compound
Percentile
P93
Near historical high
vs 3Y Ago
1.3x
Solid growth
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 45.10% |
| Q3 2025 | 34.51% |
| Q2 2025 | 15.59% |
| Q1 2025 | -7.61% |
| Q4 2024 | 2.94% |
| Q3 2024 | 24.44% |
| Q2 2024 | 11.63% |
| Q1 2024 | 15.22% |
| Q4 2023 | -8.59% |
| Q3 2023 | -24.72% |
| Q2 2023 | -31.54% |
| Q1 2023 | -65.67% |
| Q4 2022 | 34.25% |
| Q3 2022 | -338.48% |
| Q2 2022 | 73.24% |
| Q1 2022 | -35.11% |
| Q4 2021 | 8.00% |
| Q3 2021 | -315.67% |
| Q2 2021 | -32.03% |
| Q1 2021 | 193.35% |
| Q4 2020 | -13.17% |
| Q3 2020 | -210.79% |
| Q2 2020 | -54.06% |
| Q1 2020 | -95.39% |
| Q4 2019 | -71.25% |
| Q3 2019 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |